Inflarx (NASDAQ:IFRX) had its price objective decreased by investment analysts at Raymond James from $20.00 to $19.00 in a note issued to investors on Friday, BenzingaRatingsTable reports. The firm presently has an “outperform” rating on the stock. Raymond James’ price target indicates a potential upside of 278.49% from the stock’s current price.

Several other analysts also recently weighed in on IFRX. BMO Capital Markets lifted their target price on shares of Inflarx from $4.00 to $7.00 and gave the company a “market perform” rating in a report on Thursday, May 21st. SVB Leerink lifted their target price on shares of Inflarx from $4.00 to $7.00 and gave the company a “hold” rating in a report on Thursday, May 7th. Zacks Investment Research downgraded shares of Inflarx from a “buy” rating to a “hold” rating in a report on Friday, July 24th. BTIG Research started coverage on shares of Inflarx in a report on Tuesday, June 16th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, ValuEngine downgraded shares of Inflarx from a “strong-buy” rating to a “buy” rating in a report on Friday, June 5th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $9.58.

NASDAQ IFRX traded up $0.13 during trading on Friday, reaching $5.02. The company’s stock had a trading volume of 456,504 shares, compared to its average volume of 1,054,494. The firm has a market cap of $131.88 million, a price-to-earnings ratio of -2.55 and a beta of 0.55. Inflarx has a twelve month low of $2.17 and a twelve month high of $9.70. The business’s fifty day moving average price is $5.18 and its 200-day moving average price is $5.14.

Inflarx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). On average, equities analysts predict that Inflarx will post -1.31 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in IFRX. Wedbush Securities Inc. bought a new position in Inflarx during the 2nd quarter valued at $46,000. BlackRock Inc. boosted its stake in Inflarx by 40.2% during the 1st quarter. BlackRock Inc. now owns 16,473 shares of the company’s stock valued at $63,000 after acquiring an additional 4,721 shares during the last quarter. Spark Investment Management LLC bought a new position in Inflarx during the 1st quarter valued at $71,000. Raymond James Financial Services Advisors Inc. bought a new position in Inflarx during the 2nd quarter valued at $263,000. Finally, Geode Capital Management LLC boosted its stake in Inflarx by 504.7% during the 4th quarter. Geode Capital Management LLC now owns 87,779 shares of the company’s stock valued at $347,000 after acquiring an additional 73,263 shares during the last quarter. Institutional investors and hedge funds own 19.23% of the company’s stock.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

See Also: What are momentum indicators and what do they show?

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.